Biomea Fusion Inc (BMEA) - Total Assets
Based on the latest financial reports, Biomea Fusion Inc (BMEA) holds total assets worth $55.19 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Biomea Fusion Inc net assets for net asset value and shareholders' equity analysis.
Biomea Fusion Inc - Total Assets Trend (2019–2024)
This chart illustrates how Biomea Fusion Inc's total assets have evolved over time, based on quarterly financial data.
Biomea Fusion Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Biomea Fusion Inc's total assets of $55.19 Million consist of 85.5% current assets and 14.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 72.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Biomea Fusion Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Biomea Fusion Inc (BMEA) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biomea Fusion Inc's current assets represent 85.5% of total assets in 2024, a decrease from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 72.9% of total assets in 2024, down from 90.2% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Biomea Fusion Inc Competitors by Total Assets
Key competitors of Biomea Fusion Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Biomea Fusion Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.18 | 3.39 | 38.43 |
| Quick Ratio | 3.18 | 3.39 | 38.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $33.88 Million | $66.03 Million | $60.60 Million |
Biomea Fusion Inc - Advanced Valuation Insights
This section examines the relationship between Biomea Fusion Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.52 |
| Latest Market Cap to Assets Ratio | 1.08 |
| Asset Growth Rate (YoY) | -60.0% |
| Total Assets | $79.94 Million |
| Market Capitalization | $86.26 Million USD |
Valuation Analysis
Above Book Valuation: The market values Biomea Fusion Inc's assets above their book value (1.08x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Biomea Fusion Inc's assets decreased by 60.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Biomea Fusion Inc (2019–2024)
The table below shows the annual total assets of Biomea Fusion Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $79.94 Million | -60.02% |
| 2023-12-31 | $199.93 Million | +54.61% |
| 2022-12-31 | $129.31 Million | -30.37% |
| 2021-12-31 | $185.71 Million | +197.00% |
| 2020-12-31 | $62.53 Million | +23494.72% |
| 2019-12-31 | $265.00K | -- |
About Biomea Fusion Inc
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modif… Read more